Homepage - Bayer Schering Pharma

Endometriosis

News

08/31/10, Research & Development Bayer´s Rivaroxaban Successfully Meets Primary Efficacy Outcome and Demonstrates Similar Safety to Standard Therapy in Phase III EINSTEIN-DVT Non-Inferiority Study Results from EINSTEIN-DVT Study Presented at European Society of Cardiology Congress 2010 more

1
2

Special training for doctors in Tibet

Image: Tibet

It’s hard to visit a doctor in rural Tibet. With better local health care, there’s less need for costly trips to distant medical centres more

IMI – Innovative Medicines Initiative.

Project Eu2P: Master's Degree Course and PhD Program in Pharmacovigilance/ Pharmacoepidemiology more

Image: Bayer Schering Pharma celebrates 50 years of the pill

Recommended Links

Corporate Brochure
(PDF, 695 KB)

Links

Oral contra- ceptives
Information on oral contraceptives
Clinical trials
More information
Grants 4 Targets

Grants 4 Targets

We allocate grants for the further develop- ment of promising novel molecular targets. more »

Share this:

A | A | A |

© 2009 Bayer Schering Pharma Imprint

open

about 2.5 million people

About 2.5 million people world-wide suffer from multiple sclerosis, a chronic inflammatory disease of the central nervous system. We were the first company to offer a treatment option for this autoimmune disease.

more

http://www.bayerscheringpharma.de/scripts/pages/en/index.php

Copyright © Bayer Schering Pharma AG